Comments
Drug maker Lupin Monday said it has received approval from the US health regulator for Clobazam Oral Suspension, used to treat seizures associated with Lennox-Gastaut Syndrome.
The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, Lupin said in a regulatory filing.
The drug is indicated for treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients of two years of age or older.
Clobazam Oral Suspension (2.5 mg/ml) had annual sales of around $260.2 million in the US.
Lupin shares Monday ended 0.78 per cent up at ₹ 845.60 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.